Bryce Point Capital, LLC Roivant Sciences Ltd. Transaction History
Bryce Point Capital, LLC
- $81.9 Billion
- Q3 2025
A detailed history of Bryce Point Capital, LLC transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Bryce Point Capital, LLC holds 26,506 shares of ROIV stock, worth $537,806. This represents 0.49% of its overall portfolio holdings.
Number of Shares
26,506
Previous 44,528
40.47%
Holding current value
$537,806
Previous $502 Million
20.09%
% of portfolio
0.49%
Previous 0.42%
Shares
4 transactions
Others Institutions Holding ROIV
# of Institutions
374Shares Held
436MCall Options Held
6.03MPut Options Held
2.52M-
Morgan Stanley New York, NY44.3MShares$899 Million0.04% of portfolio
-
Sb Investment Advisers (Uk) LTD London, X040.3MShares$818 Million4.61% of portfolio
-
Vanguard Group Inc Valley Forge, PA38.8MShares$787 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$718 Million0.01% of portfolio
-
Qvt Financial LP New York, NY29.4MShares$596 Million36.4% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $14.3B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...